Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Breast Cancer
Published in: Breast Cancer 4/2015

01-07-2015 | Case Report

HER-2 positive primary solid neuroendocrine carcinoma of the breast: a case report and review of the literature

Authors: Guler Yavas, Pinar Karabagli, Murat Araz, Cagdas Yavas, Ozlem Ata

Published in: Breast Cancer | Issue 4/2015

Login to get access

Abstract

Primary pure neuroendocrine carcinoma of the breast is an extremely rare tumor. We report a case of primary solid neuroendocrine carcinoma in a 77-year-old postmenopausal woman who was admitted to the hospital with masses on her right breast and axillary region. Radical mastectomy with axillary lymph node resection was performed. Immunohistochemical stainings of the tumor cells with synaptophysin, GCDFP-15, estrogen, progesterone, and c-erbB-2 were positive. Five of 16 lymph nodes were metastatic. She did not receive adjuvant chemotherapy. After 15 months of follow-up she is free of the disease. Literature review revealed that this is the second case of HER-2 positive primary neuroendocrine tumor of the breast.
Literature
1.
Ellis IO, Schnitt SJ, Sastre-Garau X. Invasive breast carcinoma. In: Tavassoli FA, Devilee P, editors. WHO classification of tumors. Pathology and genetics of tumors of the breast and female genital organ. Lyon: IARC; 2003. p. 13–59.
2.
Feyrter F, Hartmann G. On the carcinoid growth form of the carcinoma mammae, especially the carcinoma solidum (Gelatinosum) mammae. Frankf Z Pathol. 1963;73:24–39.PubMed
3.
Lack EE, Cubilla AL, Woodruff JM, Farr HW. Paragangliomas of the head and neck region: a clinical study of 69 patients. Cancer. 1977;39(2):397–409.PubMedCrossRef
4.
Wick, NLR. Neuroendocrine neoplasia: an overview of current concepts and terminology. Alexandria: American Society of Clinical Oncology; 1994. p. 246–248.
5.
Richardson RL, Weiland LH. Undifferentiated small cell carcinomas extrapulmonary sites. Semin Oncol. 1982;9:484–96.PubMed
6.
Kanthan R, Negreiros F, Kanthan SC. Colonic carcinoid metastatic to the breast. Arch Pathol Lab Med. 2003;127:1373–5.PubMed
7.
8.
Akhtar K, Zaheer S, Ahmad SS, Hassan MJ. Primary neuroendocrine carcinoma of the breast. Indian J Pathol Microbiol. 2009;52:71–3.PubMedCrossRef
9.
Yaren A, Kelten C, Akbulut M, Teke Z, Duzcan E, Erdem E. Primary neuroendocrine carcinoma of the breast: a case report. Tumori. 2007;93:496–8.PubMed
10.
Stita W, Trabelsi A, Gharbi O, Mokni M, Korbi S. Primary solid neuroendocrine carcinoma of the breast. Can J Surg. 2009;52:289–90.
11.
Zhang J, Hen W. Bilateral primary breast neuroendocrine carcinoma in a young woman: report of a case. Surg Today. 2011;41:1575–8.PubMedCrossRef
12.
Fujimoto Y, Yagyu R, Murase K, Kawajiri H, Ohtani H, Arimoto Y, et al. A case of solid neuroendocrine carcinoma of the breast in a 40-year-old woman. Breast Cancer. 2007;14:250–3.PubMedCrossRef
13.
Lopez-Bonet E, Alonso-Ruano M, Barraza G, Martin A, Bernado L, Menendez JA. Solid neuroendocrine breast carcinomas: incidence, clinico-pathological features and immunohistochemical profiling. Oncol Rep. 2008;20:1369–74.PubMed
14.
Upalakalin JN, Collins LC, Tawa N, Parangi S. Carcinoid tumors in the breast. Am J Surg. 2006;191:799–805.PubMedCrossRef
15.
Richter-Ehrenstein C, Arndt J, Buckendahl A, Eucker J, Weichert W, Kasajima A, et al. Solid neuroendocrine carcinomas of the breast. Metastases or primary tumors? Breast Cancer Res Treat. 2010;124(2):413–7.PubMedCrossRef
16.
Makretsov N, Gilks CB, Coldman AJ, Hayes M, Huntsman D. Tissue microarray analysis of neuroendocrine differentiation and its prognostic significance in breast cancer. Hum Pathol. 2003;34:1001–8.PubMedCrossRef
17.
Horiguchi S, Hishima T, Hayashi Y, Shiozawa Y, Horiguchi K, Kuroi K, et al. HER-2/neu cytoplasmic staining is correlated with neuroendocrine differentiation in breast carcinoma. J Med Dent Sci. 2010;57:155–63.PubMed
18.
Bartlett JM, Going JJ, Mallon EA, et al. Evaluating HER2 amplification and overexpression in breast cancer. J Pathol. 2001;195:422–8.PubMedCrossRef
19.
Hanna W, Kahn HJ, Andrulis I, et al. Distribution and patterns of staining of Neu oncogene product in benign and malignant breast diseases. Mod Pathol. 1990;3:455–61.PubMed
Metadata
Title
HER-2 positive primary solid neuroendocrine carcinoma of the breast: a case report and review of the literature
Authors
Guler Yavas
Pinar Karabagli
Murat Araz
Cagdas Yavas
Ozlem Ata
Publication date
01-07-2015
Publisher
Springer Japan
Published in
Breast Cancer / Issue 4/2015
Print ISSN: 1340-6868
Electronic ISSN: 1880-4233
DOI
https://doi.org/10.1007/s12282-012-0382-x

Other articles of this Issue 4/2015

Breast Cancer 4/2015 Go to the issue

Original Article

Comparison of the clinicopathological features of invasive ductal, invasive lobular, and mixed (invasive ductal + invasive lobular) carcinoma of the breast

Original Article

What we should know in mammography after reduction mammoplasty and mastopexy?

Original Article

The value of progesterone receptor expression in predicting the Recurrence Score for hormone-receptor positive invasive breast cancer patients

Original Article

The feasibility of a randomised controlled trial for the axillary management of a select group of invasive breast cancer patients: SLNB vs. no-SLNB

Original Article

C4.4A highly expressed in HER2-positive human breast cancers may indicate a good prognosis

Original Article

Association of body mass index with risk of luminal A but not luminal B estrogen receptor-positive and HER2-negative breast cancer for postmenopausal Japanese women

2024 ASCO Annual Meeting Coverage

Highlights of the Day: Breast cancer – metastatic

Breast Cancer Video

In this session, Dr. Wolff provides his key takeaways from the data presented in the metastatic breast cancer oral abstract session at ASCO 2024.

Watch now

Highlights of the Day: Gynecologic cancer

Gynecologic Cancer Video

Highlights of the Day: Breast Cancer – local/regional/adjuvant

Breast Cancer Video

Neoadjuvant dual immunotherapy improves melanoma outcomes

04-06-2024 Melanoma News

» View more highlights on the ASCO 2024 congress hub page

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits